JP2003526361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003526361A5 JP2003526361A5 JP2001567302A JP2001567302A JP2003526361A5 JP 2003526361 A5 JP2003526361 A5 JP 2003526361A5 JP 2001567302 A JP2001567302 A JP 2001567302A JP 2001567302 A JP2001567302 A JP 2001567302A JP 2003526361 A5 JP2003526361 A5 JP 2003526361A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- polypeptide
- protease
- activity
- homodimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 229920001184 polypeptide Polymers 0.000 description 31
- 102000004196 processed proteins & peptides Human genes 0.000 description 31
- 238000000034 method Methods 0.000 description 19
- 108091005804 Peptidases Proteins 0.000 description 15
- 239000004365 Protease Substances 0.000 description 15
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 15
- 239000012634 fragment Substances 0.000 description 14
- 101710140962 Capsid scaffolding protein Proteins 0.000 description 11
- 239000000710 homodimer Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000000468 autoproteolytic effect Effects 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0006537.5 | 2000-03-17 | ||
| GBGB0006537.5A GB0006537D0 (en) | 2000-03-17 | 2000-03-17 | Assays and screening methods |
| PCT/IB2001/000527 WO2001068818A2 (en) | 2000-03-17 | 2001-03-14 | Hcv ns2/3 fragments and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003526361A JP2003526361A (ja) | 2003-09-09 |
| JP2003526361A5 true JP2003526361A5 (enExample) | 2008-03-13 |
Family
ID=9887885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001567302A Withdrawn JP2003526361A (ja) | 2000-03-17 | 2001-03-14 | Ｈｃｖｎｓ２／３フラグメント及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7078215B2 (enExample) |
| EP (1) | EP1278867B1 (enExample) |
| JP (1) | JP2003526361A (enExample) |
| AT (1) | ATE315093T1 (enExample) |
| AU (1) | AU4269401A (enExample) |
| CA (1) | CA2403405A1 (enExample) |
| DE (1) | DE60116474T2 (enExample) |
| ES (1) | ES2254380T3 (enExample) |
| GB (1) | GB0006537D0 (enExample) |
| WO (1) | WO2001068818A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3878132B2 (ja) | 2000-12-15 | 2007-02-07 | ベーリンガー インゲルハイム （カナダ） リミテッド | 精製活性型ｈｃｖｎｓ２／３プロテアーゼ |
| DE60304435T2 (de) * | 2004-01-19 | 2006-08-24 | Ares Trading S.A. | Verfahren zur Reinigung von in Bakterien exprimierten Proteinen |
| US20090233266A1 (en) * | 2005-03-10 | 2009-09-17 | The Rockefeller University | Structure of the hepatitis c virus ns2 protein |
| ES2386462T3 (es) * | 2005-10-28 | 2012-08-21 | Boehringer Ingelheim International Gmbh | Ensayo de la actividad NS2/3 del virus de la hepatitis C |
| EP2388312A1 (en) | 2010-05-17 | 2011-11-23 | Curetis AG | Universally applicable lysis buffer and processing methods for the lysis of bodily samples |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888762A (en) | 1990-06-05 | 1999-03-30 | Centre National De La Recherche Scientifique (Cnrs) | Neurotropic growth factors comprising a homeobox peptide |
| IT1277914B1 (it) | 1995-08-22 | 1997-11-12 | Angeletti P Ist Richerche Bio | Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e |
| US5837464A (en) * | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US6242187B1 (en) * | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US6280940B1 (en) * | 1998-08-05 | 2001-08-28 | Agouron Pharmaceuticals, Inc. | Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease |
| CA2383411A1 (en) * | 1999-08-30 | 2001-03-08 | Paul L. Darke | Hepatitis c virus replication inhibitors |
| JP3878132B2 (ja) * | 2000-12-15 | 2007-02-07 | ベーリンガー インゲルハイム （カナダ） リミテッド | 精製活性型ｈｃｖｎｓ２／３プロテアーゼ |
-
2000
- 2000-03-17 GB GBGB0006537.5A patent/GB0006537D0/en not_active Ceased
-
2001
- 2001-03-14 EP EP01915613A patent/EP1278867B1/en not_active Expired - Lifetime
- 2001-03-14 DE DE60116474T patent/DE60116474T2/de not_active Expired - Fee Related
- 2001-03-14 AU AU42694/01A patent/AU4269401A/en not_active Abandoned
- 2001-03-14 JP JP2001567302A patent/JP2003526361A/ja not_active Withdrawn
- 2001-03-14 ES ES01915613T patent/ES2254380T3/es not_active Expired - Lifetime
- 2001-03-14 CA CA002403405A patent/CA2403405A1/en not_active Abandoned
- 2001-03-14 WO PCT/IB2001/000527 patent/WO2001068818A2/en not_active Ceased
- 2001-03-14 AT AT01915613T patent/ATE315093T1/de not_active IP Right Cessation
- 2001-03-14 US US10/221,943 patent/US7078215B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532033A5 (enExample) | ||
| WO2011010304A3 (en) | Method for preparing molecularly imprinted polymers and uses thereof | |
| EP2468881A3 (en) | Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis | |
| JP2004504826A5 (enExample) | ||
| ATE344803T1 (de) | Schimärische amyloid-beta peptide | |
| WO2013083847A2 (en) | Multiplex immuno screening assay | |
| MX2009012326A (es) | Peptidos de señalizacion. | |
| DE3584260D1 (de) | Die synthese eines proteins mittels eines identifizierungspeptids. | |
| WO2007127977A3 (en) | Methods of evaluating peptide mixtures | |
| ATE272109T1 (de) | Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden | |
| UA97628C2 (ru) | Способ получения fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе | |
| DK0531404T3 (da) | Ubiquitin-specifik protease | |
| WO2004024750A3 (en) | Cd44-binding ligands | |
| CN107602706A (zh) | 一种切割效率增强的hrv3c蛋白酶底物突变体及其应用 | |
| CA2390082A1 (en) | Novel hcv non-structural polypeptide | |
| ATE540981T1 (de) | Lösliche fusionsproteine enthaltend heterologe polypeptide | |
| CA2636075A1 (en) | Chimaeric fusion protein with superior chaperone and folding activities | |
| ATE400647T1 (de) | C-terminale modifikation von polypeptiden | |
| MY157396A (en) | Novel fusion proteins and use thereof for preparing hepatitis c vaccines | |
| WO2005116660A3 (en) | Methods for making and using mass tag standards for quantitative proteomics | |
| JP2004505601A5 (enExample) | ||
| Beyer et al. | Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity | |
| Armirotti et al. | Primary structure and post-translational modifications of silicatein beta from the marine sponge Petrosia ficiformis (Poiret, 1789) | |
| CA2430661C (en) | Purified active hcv ns2/3 protease | |
| AR018045A1 (es) | Proteina placentaria 13 y polipetido, molecula de adn que los codifica, anticuerpos capaces de enlazarse a ellos, metodo para la deteccion decomplicaciones relacionadas con el embarazo, metodo recombinante para la produccion de dicha proteina y un equipo para el diagnostico de complicacionesrelacion |